242 related articles for article (PubMed ID: 16469865)
1. Novel polymeric prodrug with multivalent components for cancer therapy.
Khandare JJ; Chandna P; Wang Y; Pozharov VP; Minko T
J Pharmacol Exp Ther; 2006 Jun; 317(3):929-37. PubMed ID: 16469865
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
Conover CD; Greenwald RB; Pendri A; Shum KL
Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
[TBL] [Abstract][Full Text] [Related]
3. Targeted proapoptotic anticancer drug delivery system.
Chandna P; Saad M; Wang Y; Ber E; Khandare J; Vetcher AA; Soldatenkov VA; Minko T
Mol Pharm; 2007; 4(5):668-78. PubMed ID: 17685579
[TBL] [Abstract][Full Text] [Related]
4. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
5. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
Sarapa N; Britto MR; Speed W; Jannuzzo M; Breda M; James CA; Porro M; Rocchetti M; Wanders A; Mahteme H; Nygren P
Cancer Chemother Pharmacol; 2003 Nov; 52(5):424-30. PubMed ID: 12904897
[TBL] [Abstract][Full Text] [Related]
6. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
7. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
8. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and activity of a folate peptide camptothecin prodrug.
Henne WA; Doorneweerd DD; Hilgenbrink AR; Kularatne SA; Low PS
Bioorg Med Chem Lett; 2006 Oct; 16(20):5350-5. PubMed ID: 16901694
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel conjugation with the analog of the gonadotropin-releasing hormone as a targeting moiety.
Pribylova M; Dvorakova M; Hanusova V; Nemethova I; Skalova L; Vanek T
Int J Pharm; 2011 Aug; 415(1-2):175-80. PubMed ID: 21669266
[TBL] [Abstract][Full Text] [Related]
11. Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell.
Calderón M; Welker P; Licha K; Fichtner I; Graeser R; Haag R; Kratz F
J Control Release; 2011 May; 151(3):295-301. PubMed ID: 21256902
[TBL] [Abstract][Full Text] [Related]
12. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.
Warnecke A; Kratz F
Bioconjug Chem; 2003; 14(2):377-87. PubMed ID: 12643748
[TBL] [Abstract][Full Text] [Related]
13. Poly(ethylene glycol) anticancer drug delivery systems.
Greenwald RB
P R Health Sci J; 2002 Jun; 21(2):113-21. PubMed ID: 12166021
[No Abstract] [Full Text] [Related]
14. Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog.
Wang Y; Jiang J; Jiang X; Cai S; Han H; Li L; Tian Z; Jiang W; Zhang Z; Xiao Y; Wright SC; Larrick JW
Bioorg Med Chem; 2008 Jul; 16(13):6552-9. PubMed ID: 18508273
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan delivery by unimolecular micelles composed of reduction-responsive star-like polymeric prodrug with high drug loading for enhanced cancer therapy.
Gao YE; Bai S; Shi X; Hou M; Ma X; Zhang T; Xiao B; Xue P; Kang Y; Xu Z
Colloids Surf B Biointerfaces; 2018 Oct; 170():488-496. PubMed ID: 29960949
[TBL] [Abstract][Full Text] [Related]
16. Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library.
Schmid B; Warnecke A; Fichtner I; Jung M; Kratz F
Bioconjug Chem; 2007; 18(6):1786-99. PubMed ID: 17915955
[TBL] [Abstract][Full Text] [Related]
17. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
Wallace PM; Senter PD
Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
[TBL] [Abstract][Full Text] [Related]
18. [Construction and expression of recombinant cecropin B-binding site of luteinizing hormone releasing hormone gene and its anticancer function].
Li XY; Li HL; Zheng GY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):477-81. PubMed ID: 17961339
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
20. Ovarian tumor targeting of docetaxel-loaded liposomes mediated by luteinizing hormone-releasing hormone analogues. In vive distribution in nude mice.
Qin Y; Song QG; Zhang ZR; Liu J; Fu Y; He Q; Liu J
Arzneimittelforschung; 2008; 58(10):529-34. PubMed ID: 19025064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
